BioWorld - Friday, February 20, 2026

Neurology/psychiatric, BioWorld Science
Neurology/psychiatric, BioWorld Science RSS Feed RSS

Neurology/psychiatric

Genome-wide CRISPRi screen provides insights into tau proteostasis

Feb. 12, 2026
No Comments
Tau is an intrinsically disordered protein that regulates the stability and dynamics of microtubules in physiological conditions. Recent work has revealed the involvement of tau in various neuronal processes. Researchers from the University of California and collaborators aimed to systematically investigate the cellular factors that control the accumulation of tau aggregates in human neurons.
Read More
Illustration of baby showing brain development
Neurology/psychiatric

Targeting TRPM7 ameliorates neonatal HIBI, study finds

Feb. 11, 2026
No Comments
Hypoxic-ischemic brain injury (HIBI) is a condition affecting neonates and is a leading global cause of perinatal neurological morbidity, with limited therapeutic options. Regarding its pathogenesis, the ion channel-kinase transient receptor potential melastatin 7 (TRPM7) is a known contributor to HIBI pathology and was the focus of a recently reported study.
Read More
Illustration of DNA composing the human body
Neurology/psychiatric

Precision Biosciences’ PBGENE-DMD cleared to enter clinic

Feb. 11, 2026
No Comments
Precision Biosciences Inc. has received FDA clearance of its IND application enabling clinical trial site activation for a phase I/II trial (FUNCTION-DMD) of PBGENE-DMD for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD). The first site in the U.S. will be activated in the first half of this year.
Read More
Myelin sheath and neurons in the brain
Neurology/psychiatric

SUDO-550 demonstrates robust efficacy in MS models

Feb. 11, 2026
No Comments
TYK2, a Janus kinase family member, mediates signaling from pro-inflammatory cytokines such as type I interferons, IL-12 and IL-23. In multiple sclerosis (MS), chronic CNS inflammation involves glial activation and immune cell infiltration, making TYK2 inhibition a potential strategy to reduce neuroinflammation.
Read More
Neurology/psychiatric

Teijin Pharma and Transthera Biosciences report new ALOX15 inhibitors

Feb. 10, 2026
Fatty acid lipoxygenase ALOX15 inhibitors have been disclosed in a joint Teijin Pharma Ltd. and Transthera Biosciences Co. Ltd. patent. They are reported to be useful for the treatment of amyotrophic lateral sclerosis, asthma, autoimmune disease, cancer, cardiovascular disorders, epilepsy, Parkinson’s disease and allergic rhinitis, among others.
Read More